Youli Zu

Professor and Medical Director

Houston Methodist Hospital
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (10)

Year:

2026

Year:

2025

T cells play a critical role in the pathogenesis of systemic lupus erythematosus (SLE). Chronic T cell receptor (TCR) signalling induces T cell exhaustion, characterised by reduced capacity to induce tissue damage. Here, we investigated the therapeutic potential of the anti‐TCRβ (H57‐597) monoclonal antibody (mAb) in a mouse model of SLE. Four‐month‐old MRL/ lpr mice exhibiting SLE phenotypes received 5 weekly doses of anti‐TCRβ mAb or phosphate‐buffered saline (PBS) vehicle control. Subsequently, mouse survival was monitored daily. On day 1 post the final dose of treatment, SLE pathogenesis was determined using histological staining and spot urine test. T and B cell states in the brain, kidney, and secondary lymphoid organs were determined by flow cytometry. Transient treatment of anti‐TCRβ mAb significantly prolonged the survival of MRL/ lpr mice. Accordingly, MRL/ lpr mice in the anti‐TCRβ mAb group exhibited decreased proteinuria scores and minimal renal pathological damage compared to the PBS control group. Flow cytometric analysis revealed that anti‐TCRβ mAb treatment resulted in a reduction in the frequencies of CD4 + T cells and CD138 + B220 lo/− plasma cells, plus an increase in Foxp3 + regulatory T cell frequency. Furthermore, CD4 + T cells from anti‐TCRβ mAb treated mice exhibited elevated expression levels of PD‐1 and TIM‐3, with reduced IFN‐γ production, indicative of an exhaustion‐like phenotype. Therefore, transient administration of anti‐TCRβ mAb treatment induces an exhaustion‐like phenotype in CD4 + T cells, resulting in prolonged survival of MRL/ lpr mice. Inducing autoreactive T‐cell exhaustion holds promise as an attractive therapeutic approach for SLE.

Year:

2025

Year:

2025

Year:

2025

Pyroptosis is a form of programmed cell death characterized by the cleavage of gasdermin (GSDM) family proteins that form pores in the plasma membrane, cell rupture, and the release of pro-inflammatory cytokines. In this study, we performed immunohistochemistry for cleaved GSDMD, GSDME-N-terminal, and GSDMC in two different cohorts of diffuse large B-cell lymphoma (DLBCL), and analyzed their prognostic and immune impact. The results showed frequent cleaved GSDMD (GSDMD-N-terminal) expression. Only cytoplasmic GSDMD-N-terminal expression correlated with significantly better patient survival in two cohorts. In contrast, GSDME was mainly expressed in the vascular endothelium, correlated with significantly adverse prognostic effect. Correlating with the multiplex fluorescent immunohistochemistry (mfIHC) results, we found that cytoplasmic GSDMD-N-terminal expression was associated with increased CD38+ (activated) M1 macrophages in both cohorts, cognate interactions between live DLBCL cells and activated M1 macrophages (and T cells), and lower PD-1/PD-L1 expression in the analyzed cases. In contrast, T cell pyroptosis, lymphoma cell resistance to cell death, and phagocytosis by M2 macrophages were observed in cells with nuclear GSDMD-N-terminal expression. Bulk gene expression profiling and deconvolution analysis for patients with cytoplasmic GSDMD-N-terminal expression revealed downregulation of "Don't eat me" signaling genes, upregulation of many RNA genes, decreased frequency of "Inflammatory" lymphoma microenvironment subtype, increased abundance of prognostically favorable cell states and ecotypes, and decreased abundance of T cell exhaustion state. In summary, this study showed distinct cellular and subcellular patterns of three gasdermin proteins and their associated immune response phenotypes and prognostic effects, with implications for novel therapeutic strategies for B-cell lymphoma.

Year:

2025

Background: Pyroptosis is a form of programmed cell death characterized by cleavage of gasdermin (GSDM) family proteins that form pores in the plasma membrane, cell rupture, and release of pro-inflammatory cytokines. Its pro-inflammatory potential has garnered significant research attention in recent years but has not been studied in lymphoma. Patients and Methods: We performed immunohistochemistry for cleaved GSDMD (n-terminal) in two large cohorts of diffuse large B-cell lymphoma (DLBCL) with multiplex fluorescent IHC (mfIHC) data, and analyzed for prognostic and immune impact. Results: Cleaved GSDMD was frequently expressed in DLBCL, and only the cytoplasmic (versus nuclear) form of expression correlated with significantly better patient survival in two DLBCL cohorts. To understand the expression at the single-cell level, we examined mfIHC results, which revealed that GSDMD+cells were tumor or immune cells, and varied in Ki-67, BCL2, and MYC expression. Cases with cytoplasmic cleaved GSDMD expression had higher mean and median levels of CD38+ (activated) M1 macrophages in two cohorts and lower PD-1/PD-L1 expression, as well as phenotypes of cognate interactions between live activated M1 macrophages, DLBCL cells, and T cells in spatially resolved immune landscape by mfIHC. In contrast, phagocytosis of pyroptotic lymphoma cells by M2 macrophages and cell death of T cells were observed in cases with predominantly nuclear form of cleaved GSDMD expression. Bulk gene expression profiling analysis identified a large proportion of RNA genes upregulated in DLBCLs with cytoplasmic cleaved GSDMD expression, and deconvolution analysis found decreased frequency of the “Inflammatory” lymphoma microenvironment (LME) subtype, increased frequency of cell states and ecotypes with favorable prognostic associations, and decreased frequency of T cell exhaustion states. Summary: Analysis of pyroptosis-inducing cleaved GSDMD (n-terminal) expression in a large number of DLBCL patients revealed dinstinctive cytoplasmic and nuclear expression patterns in live and pyroptotic cells associated with different prognostic and immune effects. Cytoplasmic cleaved GSDMD expression is a marker of cognate interactions between live cells (e.g., activated M1 macrophages) associated with adaptive responses and favorable prognostic effects, whereas nuclear cleaved GSDMD expression is associated with immunosuppressive mechanisms, including T cell death and phagocytosis by M2 macrophages.

Year:

2025

Background: Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL), accounting for approximately 30% of all NHL cases. DLBCL diagnosis relies on histologic examination, immunophenotyping, molecular and fluorescence in situ hybridization (FISH) analysis to differentiate it from similar NHL subtypes with overlapping morphological features, including more high-grade lymphomas like double-hit lymphoma. Because FISH is performed in a panel of single- or dual-target test format and analyzed through microscopy and manual image analysis, assessment of multiple target biomarkers can be cumbersome and expensive. As additional biomarkers for diagnosis, subtyping, prognosis, and therapeutic decision-making become available, target panels will become larger, posing additional challenges to clinical laboratories. Patients and Methods In this study, Hi-C sequencing of FFPE samples was performed to identify all genomic rearrangements by a single sequencing analysis for an unselected DLBCL case series of 159 patients, and the results were compared to FISH for the detection of clinically important variants. Results Hi-C sequencing showed superior performance compared to FISH: standard FISH for DLBCL includes testing for MYC, BCL2, and BCL6. Between FISH and Hi-C, these biomarkers were detected 105 times, of which, FISH detected 80/105 (76%) and Hi-C detected 102/105 (97%). The cohort included 4 double-hit lymphomas by FISH but Hi-C sequencing detected five. Besides DLBCL diagnostic biomarkers (MYC, BCL2, BCL6), many additional biomarkers were detected by Hi-C sequencing including variants not tested by FISH because the clinical suspicion was ambiguous and the relevant FISH probes were not used, and those not tested because the biomarkers were not thought to be common and, hence, left out of the FISH panel. In total, Hi-C sequencing detected additional biomarkers in 42 (26%) cases, including (1) variants targeted by FISH (i.e. MYC, BCL2, BCL6) but negative, (2) classification biomarkers for other lymphomas (CCND1, MALT, IRF4), and (3) those not tested because the biomarkers are not common and not included in the FISH panel. These additional biomarkers were supportive of suspected diagnosis of DLBCL versus double-hit lymphoma (24 cases), prompted reconsideration of a different diagnosis that may have led to different treatments (6 cases, e.g. mantle cell lymphoma), or biomarkers such as PDL1, ALK, and ATM which have implications for targeted therapies and/or inclusion in clinical trials (5 cases). Conclusion The Hi-C FFPE sequencing technology has the potential to improve the workflow of pathology labs for detection of a wide range of structural variants informing precision diagnosis and treatment for lymphomas.

Year:

2025

Background Cholesterol metabolism reprogramming is a hallmark of cancer cells that exhibit cholesterol addiction by absorbing low-density lipoprotein (LDL) to generate cholesterol for growth. Yet the underlying mechanisms remain unclear. Methods We began by identifying Niemann-Pick C1 (NPC1) as a key cholesterol uptake gene linked to cancer progression through clinical data analysis. Using three tumor models, we showed that NPC1 promotes tumor growth by suppressing pyroptosis. Finally, we demonstrated that the NPC1 inhibitor U18666A effectively inhibits tumor growth, supporting its therapeutic potential. Results Here we report that NPC1, a key player in cholesterol transport, protects cancer cells from pyroptosis across multiple cancer types. NPC1 expression was highly elevated in human cancers and negatively correlated with patient survival. NPC1 deficiency led to reduced cancer growth and enhanced sensitivity to pyroptosis under pyroptotic stress. NPC1 protects cancer cells from pyroptosis by maintaining cholesterol homeostasis and facilitating LDL-mediated cholesterol uptake, leading to enhanced geranylgeranyl pyrophosphate synthesis for cancer cell survival. Moreover, NPC1 inhibitor U18666A induced cancer cell pyroptosis and was highly therapeutic, either alone or combined with chemotherapeutics, against human hematologic and solid cancers in xenograft mouse models. Conclusion This study reveals that NPC1 may be a potential therapeutic target for the treatment of human cancers.

Year:

2025

Description Pyroptosis has emerged as a novel form of programmed cell death implicated in tumorigenesis and antitumor immunity. To gain knowledge on the role of pyroptosis in diffuse large B-cell lymphoma (DLBCL), we assessed expression of cleaved gasdermin D (GSDMD), GSDME, and GSDMC by immunohistochemistry (IHC) in a large number of DLBCL specimens, and correlated the expression to patient survival and immune biomarkers quantified by multiplex fluorescent IHC, separately in two subcohorts treated by R-CHOP or CHOP chemotherapy. We found that cleaved GSDMD cytoplasmic expression was significantly associated with better survival of patients with DLBCL, increased CD38+ M1-like macrophages (CD68+CD163- or CD11c+), and higher CD38+ percentages in both two subcohorts, as well as lower PD-L1 expression in macrophages and PD-1 expression in T cells in the R-CHOP cohort (PD-1 and PD-L1 were not evaluated in the CHOP cohort). In contrast, GSDME was mainly expressed in endothelial cells, and showed significantly unfavorable prognostic effects and associations with higher CD31+ and CD3+ cell densities in both two subcohorts. In addition, GSDME+ and high GSDMC expression were associated with higher CD38+ cell densities (including CD38+ M1-like macrophages) and percentages in the R-CHOP cohort, whereas GSDME+ was associated with increased M2-like macrophages in the CHOP cohort. Together, these prognostic and correlative results indicate that gasdermins and pyroptosis have important roles in DLBCL. Funding Sources R01CA233490, Duke University startup fund Topic Categories Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)

Year:

2025

Collaborators (18)

Karen Dybkaer

Aalborg University

DENMARK
View details

Bangchen Wang

Assistant Professor

Duke University Medical Center

UNITED STATES
View details

Fnu Alnoor

Clinical Assistant Professor

University of Miami Hospital

UNITED STATES
View details

Govind Bhagat

Professor and Chair

Saint Louis University School of Medicine

UNITED STATES
View details

Wei Xie

Assistant professor

Oregon Health & Science University

UNITED STATES
View details

Ken H. Young

Professor

Duke University Medical Center

UNITED STATES
View details

Alexander Xu

Assistant Professor

University of Maryland at College Park

UNITED STATES
View details

Binh Vu

Research Assistant Professor

University of Houston

UNITED STATES
View details

Jacinta C. Conrad

University of Houston

UNITED STATES
View details

Richard Willson

Professor

University of Houston

UNITED STATES
View details

Peng Li

University of Utah Health

UNITED STATES
View details

Fenghuang Zhan

Professor, Morrison Family Endowed Chair

University of Arkansas for Medical Sciences

UNITED STATES
View details

Leon Bernal-Mizrachi

Professor and Chair

Wake Forest Baptist Medical Center

UNITED STATES
View details

Zhenming Xu

Associate Professor

University of Texas Health Science Center at San Antonio

UNITED STATES
View details

Nancy Gonzalez

Houston Methodist Research Institute

UNITED STATES
View details

Alexandar Tzankov

Head Histopathology and Autopsy

University Hospital Basel

SWITZERLAND
View details

Henry Withers

Research Assistant Professor of Oncology

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Wenhao Chen

Houston Methodist Research Institute

UNITED STATES
View details